Merck's Ebola Vaccine Showed 84% Effectiveness During Large Outbreak In Africa
Merck's Ebola Vaccine Showed 84% Effectiveness During Large Outbreak In Africa
The data showed that 1,273 (4·8%) of 26,438 eligible individuals were positive for Ebola virus disease (cases), and 25,165 (95·2%) were negative (controls).Merck & Co Inc's (NYSE:MRK) rVSV-ZEBOV vaccine is the only WHO-prequalified vaccine endorsed by the Strategic Advisory Group of Experts on Immunization for use in Ebola outbreaks caused by the Zaire ebolavirus.
默沙東公司的rVSV-ZEBOV疫苗是世界衛生組織預認證的唯一一種生物-疫苗，也是由免疫戰略諮詢專家組認可用於由扎伊爾伊博拉病毒引起的埃博拉疫情的疫苗。
The FDA approved the vaccine for adults in December 2019 and for use in children 12 months and older in August 2023.
FDA於2019年12月批准該疫苗供成年人使用，並於2023年8月批准供12個月及以上的兒童使用。
Researchers conducted a retrospective test-negative analysis to estimate the effectiveness of rVSV-ZEBOV vaccination against Ebola virus disease during the 2018–20 epidemic in the Democratic Republic of the Congo.
研究人員進行了一項回顧性負陰性分析，估計了rVSV-ZEBOV疫苗在剛果民主共和國2018-20年疫情期間對埃博拉病毒疾病的有效性。
The data showed that 1,273 (4·8%) of 26,438 eligible individuals were positive for Ebola virus disease (cases), and 25,165 (95·2%) were negative (controls).
數據顯示，在26,438名符合條件的個體中，有1,273人（4.8％）被檢測出感染埃博拉病毒（病例），25,165人（95.2％）爲陰性（對照組）。
Also Read: Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst.
同時閱讀：默沙東以13億美元收購潛在的免疫性疾病候選者對Cullinan的調查藥物具有相關意義，分析師表示。
40 (3·1%) cases and 1271 (5·1%) controls were reported as being vaccinated at least ten days before symptom onset.
有40例（3.1％）病例和1271例（5.1％）對照報道稱症狀出現前至少十天接種了疫苗。
After selecting individuals who reported exposure to an individual with Ebola virus disease within 21 days before symptom onset and matching, the analysis datasets comprised a median of 309 cases and 309 controls.
在選擇報告在症狀出現前21天內接觸到埃博拉病毒感染者的個體並進行匹配後，分析數據集包括了一箇中位數爲309例病例和309例對照。
Ten days or more after vaccination, the effectiveness of rVSV-ZEBOV against Ebola virus disease was estimated to be 84%.
疫苗接種後十天或更長時間，rVSV-ZEBOV對埃博拉病毒疾病的有效性估計爲84％。
The researchers add that the analysis provides the first real-world effectiveness estimates for the rVSV-ZEBOV Ebola vaccine during a large outbreak.
研究人員補充說，這項分析提供了rVSV-ZEBOV埃博拉疫苗在大規模爆發期間的首個實際有效性估計。
The findings confirm the vaccine is highly effective against Ebola virus disease and support its use in outbreaks, even in challenging environments like the Eastern Democratic Republic of the Congo.
研究結果證實了該疫苗對埃博拉病毒疾病的高度有效性，並支持其在爆發期間的使用，即使在像剛果民主共和國東部這樣具有挑戰性的環境中也是如此。
The real-world effectiveness of rVSV-ZEBOV vaccination is expected to be less than 100%.
rVSV-ZEBOV疫苗的實際有效性預計低於100%。
During the 2018–20 outbreak in the Democratic Republic of the Congo, national and international agencies recorded confirmed cases of Ebola virus disease in vaccinated individuals, including individuals who were reported as having been vaccinated ten days or more before symptom onset.
在剛果民主共和國2018年至2020年的疫情期間，國家和國際機構記錄了接種rVSV-ZEBOV疫苗的人員中的埃博拉病毒疾病確診病例，包括在出現症狀起十天或更長時間之前接種疫苗的人員。
Preliminary, unadjusted analyses estimated vaccine effectiveness to be 98%. Other studies have shown that rVSV-ZEBOV vaccination reduces the risk of death in patients with Ebola virus disease who were vaccinated before and even after exposure.
初步、未經調整的分析估計該疫苗的有效性爲98%。其他研究表明，rVSV-ZEBOV疫苗降低了已接種疫苗的埃博拉病毒疾病患者死亡風險，甚至在暴露之前和之後的接種都有效。
Price Action: MRK stock is up 0.16% to $116.22 at the last check on Thursday.
股票價格：默沙東股票最近一次檢查時上漲0.16%，至116.22美元。
- TransMedics' Technology Poised To Transform Underpenetrated $8B Organ Transplant Market, Analyst Expects 22% Upside.
- transmedics公司的科技有望改變80億美元的器官移植市場，並增加22%的上漲空間，分析師預計。
